Syngene International Limited (NSE:SYNGENE)
434.85
-0.20 (-0.05%)
Feb 17, 2026, 10:40 AM IST
Syngene International Revenue
Syngene International had revenue of 9.17B INR in the quarter ending December 31, 2025, a decrease of -2.82%. This brings the company's revenue in the last twelve months to 37.20B, up 5.05% year-over-year. In the fiscal year ending March 31, 2025, Syngene International had annual revenue of 36.42B with 4.41% growth.
Revenue (ttm)
37.20B
Revenue Growth
+5.05%
P/S Ratio
4.66
Revenue / Employee
5.69M
Employees
6,533
Market Cap
173.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
| Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
| Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
| Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
| Mar 31, 2021 | 21.84B | 1.72B | 8.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Cipla | 279.67B |
| Apollo Hospitals Enterprise | 242.15B |
| Divi's Laboratories | 103.14B |
| Piramal Pharma | 88.71B |
| Alembic Pharmaceuticals | 72.67B |
| NATCO Pharma | 45.63B |
| Eris Lifesciences | 30.65B |
Syngene International News
- 21 days ago - Syngene International shares fall sharply over 7% today: Details here - Business Upturn
- 24 days ago - Syngene International Ltd (BOM:539268) Q3 2026 Earnings Call Highlights: Navigating Revenue ... - GuruFocus
- 24 days ago - Q3 2026 Syngene International Ltd Earnings Call Transcript - GuruFocus
- 4 weeks ago - Syngene International extends strategic collaboration with Bristol Myers Squibb Till 2035 - Business Upturn
- 2 months ago - Syngene International Ltd Webinar on Clinical Trials Market Call Transcript - GuruFocus
- 3 months ago - Syngene International Ltd (BOM:539268) Q2 2026 Earnings Call Highlights: Navigating Growth ... - GuruFocus
- 3 months ago - Q2 2026 Syngene International Ltd Earnings Call Transcript - GuruFocus
- 7 months ago - Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains - Business Upturn